Urology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Miller J et al. - Medical treatments of symptomatic BPH include; 1) the 5alpha-reductase inhibitors, 2) the alpha1-adrenergic antagonists, and 3) the combination of a 5alpha-reductase inhibitor and a alpha1-adrenergic antagonist. Selective alpha1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that alpha1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5alpha-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5alpha-reductase inhibitor dutasteride and the alpha1-adrenergic antagonist tamsulosin offer significant improvements from baseline compared with either drug alone.

Related Articles

The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery
BJU International, 11/09/09    Relevance Score: 66%

Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer
BJU International, 11/06/09    Relevance Score: 66%

A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate
International Urology and Nephrology, 11/04/09    Relevance Score: 64%

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
Indian Journal of Urology, 10/05/09    Relevance Score: 63%

Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/16/09    Relevance Score: 48%

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address